| | NOS | Tip | Perihilar |
|---|
| | N (%) | /1000 pys | N (%) | /1000 pys | N (%) | /1000 pys |
|---|
Composite* | 12 (17.1%) | 47.6 | 1 (5.0%) | 17.8 | 2 (11.8%) | 45.2 |
D-SCr | 12 (17.1%) | 47.6 | 1 (5.0%) | 17.8 | 2 (11.8%) | 45.2 |
ESRD | 8 (11.4%) | 31.3 | 1 (5.0%) | 17.6 | 0 (0.0%) | 0.0 |
CR or PR | 38 (54.3%) | 337.5 | 16 (80.0%)†, ‡
| 678.0 | 7 (41.2%) | 220.8 |
CR | 16 (22.9%) | 84.7 | 10 (50.0%)§, #
| 305.8 | 3 (17.6%) | 74.1 |
PR | 22 (31.4%) | 153.8 | 6 (30.0%) | 155.8 | 4 (23.5%) | 112.4 |
Relapse | 8 (11.4%) | | 3 (15.0%) | | 1 (5.9%) | |
- *Composite outcome was a doubling of the baseline serum creatinine concentration or ESRD.
- †, P = 0.038 vs. NOS; ‡, P = 0.015 vs. perihilar; §, P = 0.018 vs. NOS; #, P = 0.040 vs. perihilar.
-
Abbreviations: NOS not-otherwise specified, D-SCr doubling of the baseline creatinine levels, ESRD end-stage renal disease, CR complete remission, PR partial remission, pys patient-years.
- Footnote; Thirty-five patients achieved partial remission. Thirty-two cases are included in Table 2 and the remaining 3 cases are two patients with cellular variant and a patient with collapsing variant.
